PRL and B-cell chronic lymphocytic leukemia: A retrospective analysis of 123 CLL patients who discontinued ibrutinib- or idelalisib-based therapy found that many patients who discontinued these therapies due to toxicity or progression responded to other therapies (40% PR + PRL to nonkinase inhibitors and 60–67% to other kinase inhibitor therapy) [70].